Departement
Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Zurück
Publications Marzolini Catia

Antiretroviral drug exposure and response in obese and morbidly obese people with HIV: a study combining modelling and Swiss HIV Cohort data.

Berton M; Bettonte S; Stader F; Decosterd L; Tarr PE; Livio F; Cavassini M; Braun DL; Kusejko K; Hachfeld A; Bernasconi E; Calmy A; Schmid P; Battegay M; Marzolini C. Clinical Infectious Diseases. 2023.

Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study.

Schwenke JM; Thorball CW; Schoepf IC; Ryom L; Hasse B; Lamy O; Calmy A; Wandeler G; Marzolini C; Kahlert CR; Bernasconi E; Kouyos RD; Günthard HF; Ledergerber B; Fellay J; Burkhalter F; Tarr PE; Swiss HIV Cohort Study. Journal of Infectious Diseases. 2023.

Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole.

Haefliger D; Marzolini C; Lamoth F; Pabst T; Buclin T; Livio F. . 2023.

Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen.

Marzolini C; Cavassini M; Braun DL; Hachfeld A; Bernasconi E; Calmy A; Schmid P; Battegay M; Elzi L; Swiss HIV Cohort Study. British Journal of Clinical Pharmacology. 2023.

Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years.

Schoepf IC; Esteban-Cantos A; Thorball CW; Rodés B; Reiss P; Rodríguez-Centeno J; Riebensahm C; Braun DL; Marzolini C; Seneghini M; Bernasconi E; Cavassini M; Buvelot H; Thurnheer MC; Kouyos RD; Fellay J; Günthard HF; Arribas JR; Ledergerber B; Tarr PE; Swiss HIV Cohort Study. The lancet. Healthy longevity. 2023.

Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers.

Berton M; Bettonte S; Stader F; Battegay M; Marzolini C. Open Forum Infectious Diseases. 2023.

Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen.

Bettonte S; Berton M; Stader F; Battegay M; Marzolini C. British Journal of Clinical Pharmacology. 2023.

Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?

Sebastiani G; Milic J; Tsochatzis EA; Marzolini C; Betel M; Bhagani S; Morse CG; Cinque F; Maurice JB; Ingiliz P; Price J; Lemoine M; Rockstroh JK; Guaraldi G; Steatohepatitis in HIV Emerging Research (SHIVER) Network. Hepatology. 2023.

Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study.

Avery EF; Kleynhans JN; Ledergerber B; Schoepf IC; Thorball CW; Kootstra NA; Reiss P; Ryom L; Braun DL; Thurnheer MC; Marzolini C; Seneghini M; Bernasconi E; Cavassini M; Buvelot H; Kouyos RD; Fellay J; Günthard HF; Tarr PE; Swiss HIV Cohort Study. Clinical Infectious Diseases. 2023.

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.

Bettonte S; Berton M; Stader F; Battegay M; Marzolini C. Clinical Infectious Diseases. 2023.

Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates.

Bettonte S; Berton M; Stader F; Battegay M; Marzolini C. European journal of drug metabolism and pharmacokinetics. 2023.

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals.

Berton M; Bettonte S; Stader F; Battegay M; Marzolini C. Clinical Pharmacokinetics. 2023.

Response to "A Case Report of Safe Coadministration of Amioradone With Short-Term Treatment Nirmatrelvir-Ritonavir".

Marzolini C; Khoo S. . 2023.

Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient.

Erba A; Marzolini C; Rentsch K; Stoeckle M; Battegay M; Mayr M; Weisser M. Virology Journal. 2023.

What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?

Bettonte S; Berton M; Marzolini C. . 2023.

Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus.

Jakeman B; Scherrer AU; Darling KEA; Damas J; Bieler-Aeschlimann M; Hasse B; Schlosser L; Hachfeld A; Gutbrod K; Tarr PE; Calmy A; Assal F; Kunze U; Stoeckle M; Schmid P; Toller G; Rossi S; di Benedetto C; du Pasquier R; Cavassini M; Marzolini C; NAMACO Study Group, a Swiss HIV Cohort Study. Open Forum Infectious Diseases. 2022.

Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study.

Jakeman B; Scherrer A; Battegay M; Gunthard HF; Hachfeld A; Calmy A; Schmid P; Bernasconi E; Cavassini M; Marzolini C. Journal of Antimicrobial Chemotherapy. 2022.

Cohort Profile Update: The Swiss HIV Cohort Study (SHCS).

Scherrer AU; Traytel A; Braun DL; Calmy A; Battegay M; Cavassini M; Furrer H; Schmid P; Bernasconi E; Stoeckle M; Kahlert C; Trkola A; Kouyos RD; Tarr P; Marzolini C; Wandeler G; Fellay J; Bucher H; Yerly S; Suter F; Hirsch H; Huber M; Dollenmaier G; Perreau M; Martinetti G; Rauch A; Günthard HF; Swiss HIV Cohort Study (SHCS). International Journal of Epidemiology. 2022.

Collaborative Challenges of Multi-Cohort Projects in Pharmacogenetics-Why Time Is Essential for Meaningful Collaborations.

Franchini F; Kusejko K; Marzolini C; Tellenbach C; Rossi S; Stampf S; Koller M; Stoyanov J; Möller B; Leichtle AB. JMIR formative research. 2022.

Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.

Jacobs TG; Marzolini C; Back DJ; Burger DM. Journal of Antimicrobial Chemotherapy. 2022.

Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.

Marzolini C; Gibbons S; van Oosterhout JJ; Khoo S. Clinical Pharmacokinetics. 2022.

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.

Girardin F; Manuel O; Marzolini C; Buclin T. Clinical Microbiology and Infection. 2022.

Fluvoxamine for the treatment of COVID-19.

Marzolini C; Marra F; Boyle A; Khoo S; Back DJ. . 2022.

Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.

Zino L; Kingma JS; Marzolini C; Richel O; Burger DM; Colbers A. Clinical Pharmacokinetics. 2022.

Magnitude of Drug-Drug Interactions in Special Populations.

Bettonte S; Berton M; Marzolini C. Pharmaceutics. 2022.

Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.

Ryom L; De Miguel R; Cotter AG; Podlekareva D; Beguelin C; Waalewijn H; Arribas JR; Mallon PWG; Marzolini C; Kirk O; Bamford A; Rauch A; Molina JM; Kowalska JD; Guaraldi G; Winston A; Boesecke C; Cinque P; Welch S; Collins S; Behrens GMN; EACS Governing Board. HIV Medicine. 2022.

Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.

Stader F; Battegay M; Sendi P; Marzolini C. Clinical Pharmacology and Therapeutics. 2022.

Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.

Otten LS; Piet B; van den Heuvel MM; Marzolini C; van Geel RMJM; Gulikers JL; Burger DM; Leentjens J; Ter Heine R. European respiratory review : an official journal of the European Respiratory Society. 2022.

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.

Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back D; Khoo S. . 2022.

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.

Thoueille P; Alves Saldanha S; Schaller F; Munting A; Cavassini M; Braun D; Günthard HF; Kusejko K; Surial B; Furrer H; Rauch A; Ustero P; Calmy A; Stoeckle M; Battegay M; Marzolini C; Andre P; Guidi M; Buclin T; Decosterd LA; On Behalf Of The Swiss Hiv Cohort Study. Pharmaceutics. 2022.

Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.

Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S. Clinical Pharmacology and Therapeutics. 2022.

Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models.

Berton M; Bettonte S; Stader F; Battegay M; Marzolini C. Clinical Pharmacokinetics. 2022.

Sex-related pharmacokinetic differences with aging.

Stader F; Marzolini C. European geriatric medicine. 2022.

Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years.

Schoepf IC; Thorball CW; Ledergerber B; Kootstra NA; Reiss P; Raffenberg M; Engel T; Braun DL; Hasse B; Thurnheer C; Marzolini C; Seneghini M; Bernasconi E; Cavassini M; Buvelot H; Arribas JR; Kouyos RD; Fellay J; Günthard HF; Tarr PE. Journal of Infectious Diseases. 2022.

Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.

Aebi-Popp K; Kahlert CR; Crisinel PA; Decosterd L; Saldanha SA; Hoesli I; Martinez De Tejada B; Duppenthaler A; Rauch A; Marzolini C; Swiss Mother and Child HIV Cohort Study (SHCS). Journal of Antimicrobial Chemotherapy. 2022.

Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity.

Livio F; Deutschmann E; Moffa G; Rrustemi F; Stader F; Elzi L; Braun DL; Calmy A; Hachfeld A; Cavassini M; Tarr PE; Wissel K; Battegay M; Marzolini C; Swiss HIV Cohort Study. Journal of Antimicrobial Chemotherapy. 2021.

Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre.

Istampoulouoglou I; Zimmermanns B; Grandinetti T; Marzolini C; Harings-Kaim A; Koechlin-Lemke S; Scholz I; Bassetti S; Leuppi-Taegtmeyer AB. Global cardiology science & practice. 2021.

Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly.

Stader F; Courlet P; Kinvig H; Penny MA; Decosterd LA; Battegay M; Siccardi M; Marzolini C. Clinical Pharmacology and Therapeutics. 2021.

Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study.

Roth JA; Radevski G; Marzolini C; Rauch A; Günthard HF; Kouyos RD; Fux CA; Scherrer AU; Calmy A; Cavassini M; Kahlert CR; Bernasconi E; Bogojeska J; Battegay M; Swiss HIV Cohort Study (SHCS). Journal of Infectious Diseases. 2021.

Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study.

Schoepf IC; Thorball CW; Ledergerber B; Engel T; Raffenberg M; Kootstra NA; Reiss P; Hasse B; Marzolini C; Thurnheer C; Seneghini M; Bernasconi E; Cavassini M; Buvelot H; Kouyos R; Günthard HF; Fellay J; Tarr PE; Swiss HIV Cohort Study. Clinical Infectious Diseases. 2021.

COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.

Back D; Marzolini C; Hodge C; Marra F; Boyle A; Gibbons S; Burger D; Khoo S. . 2021.

Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation.

Stader F; Courlet P; Kinvig H; Battegay M; Decosterd LA; Penny MA; Siccardi M; Marzolini C. British Journal of Clinical Pharmacology. 2021.

Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance.

Mari A; Roloff T; Stange M; Søgaard KK; Asllanaj E; Tauriello G; Alexander LT; Schweitzer M; Leuzinger K; Gensch A; Martinez AE; Bielicki J; Pargger H; Siegemund M; Nickel CH; Bingisser R; Osthoff M; Bassetti S; Sendi P; Battegay M; Marzolini C; Seth-Smith HMB; Schwede T; Hirsch HH; Egli A. Microorganisms. 2021.

Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature.

Hollinger A; Cueni N; Marzolini C; Dickenmann M; Landmann E; Battegay M; Martinez AE; Siegemund M; Leuppi-Taegtmeyer A. AIDS Research and Therapy. 2021.

Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.

Courlet P; Guidi M; Alves Saldanha S; Stader F; Traytel A; Cavassini M; Stoeckle M; Buclin T; Marzolini C; Decosterd LA; Csajka C; and the Swiss HIV Cohort Study. Clinical Pharmacokinetics. 2021.

Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.

Hodge D; Back DJ; Gibbons S; Khoo SH; Marzolini C. Clinical Pharmacokinetics. 2021.

Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.

Stader F; Courlet P; Decosterd LA; Battegay M; Marzolini C. . 2021.

Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.

Stader F; Battegay M; Marzolini C. Clinical Pharmacology and Therapeutics. 2021.

Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drug-drug interactions?

Allavena C; Marzolini C. . 2021.

Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drug-drug interactions?

Allavena C; Marzolini C. . 2021.

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.

Courlet P; Guidi M; Alves Saldanha S; Cavassini M; Stoeckle M; Buclin T; Marzolini C; Decosterd LA; Csajka C. European Journal of Clinical Pharmacology. 2021.

Prescribing in COVID-19 patients: Should we take into account inflammation?

Marzolini C; Battegay M; Sendi P; Back DJ. British Journal of Clinical Pharmacology. 2021.

Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors.

Deutschmann E; Bucher HC; Jaeckel S; Gibbons S; McAllister K; Scherrer AU; Braun DL; Cavassini M; Hachfeld A; Calmy A; Battegay M; Cipriani M; Elzi L; Young J; Lopez-Centeno B; Berenguer J; Khoo S; Moffa G; Marzolini C; Swiss HIV Cohort Study. Clinical Infectious Diseases. 2021.

Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study.

Kuemmerle A; Sikalengo G; Vanobberghen F; Ndege RC; Foe G; Schlaeppi C; Burri C; Battegay M; Paris DH; Glass TR; Weisser M; Marzolini C; KIULARCO Study Group. Journal of Antimicrobial Chemotherapy. 2021.

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.

Marra F; Smolders EJ; El-Sherif O; Boyle A; Davidson K; Sommerville AJ; Marzolini C; Siccardi M; Burger D; Gibbons S; Khoo S; Back D. Drugs in R&D. 2021.

Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.

Marzolini C; Stader F; Leuppi-Taegtmeyer A; Stoeckle M; Battegay M; Sendi P. . 2021.

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.

Ryom L; Cotter A; De Miguel R; Béguelin C; Podlekareva D; Arribas JR; Marzolini C; Mallon P; Rauch A; Kirk O; Molina JM; Guaraldi G; Winston A; Bhagani S; Cinque P; Kowalska JD; Collins S; Battegay M; EACS Governing Board. HIV Medicine. 2020.

Aging does not impact drug--drug interaction magnitudes with antiretrovirals.

Stader F; Decosterd L; Stoeckle M; Cavassini M; Battegay M; Saldanha SA; Marzolini C; Courlet P; and the Swiss HIV Cohort Study. AIDS. 2020.

Cobicistat: A case of mislabelled drug-drug interaction risk?

Burger DM; Calmy A; Marzolini C. . 2020.

Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.

Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA. Journal of Mass Spectrometry. 2020.

Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?

Bukkems VE; Colbers A; Marzolini C; Molto J; Burger DM. Clinical Pharmacokinetics. 2020.

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Hodge D; Marra F; Marzolini C; Boyle A; Gibbons S; Siccardi M; Burger D; Back D; Khoo S. Journal of Antimicrobial Chemotherapy. 2020.

Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.

Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P. Antimicrobial Agents and Chemotherapy. 2020.

Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.

Courlet P; Decosterd LA; Alves Saldanha S; Cavassini M; Stader F; Stoeckle M; Buclin T; Marzolini C; Csajka C; Guidi M; Swiss HIV Cohort Study. Clinical Pharmacokinetics. 2020.

New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.

Guaraldi G; Maurice JB; Marzolini C; Monteith K; Milic J; Tsochatzis E; Bhagani S; Morse CG; Price JC; Ingiliz P; Lemoine M; Sebastiani G; SHIVER Network. Hepatology. 2020.

Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.

Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C; Swiss HIV Cohort Study. AIDS. 2020.

Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.

Stader F; Kinvig H; Penny MA; Battegay M; Siccardi M; Marzolini C. Clinical Pharmacokinetics. 2020.

Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study.

López-Centeno B; Badenes-Olmedo C; Mataix-Sanjuan Á; McAllister K; Bellón JM; Gibbons S; Balsalobre P; Pérez-Latorre L; Benedí J; Marzolini C; Aranguren-Oyarzábal A; Khoo S; Calvo-Alcántara MJ; Berenguer J. Clinical Infectious Diseases. 2020.

Potentially inappropriate medications in older adults living with HIV.

López-Centeno B; Badenes-Olmedo C; Mataix-Sanjuan A; Bellón JM; Pérez-Latorre L; López JC; Benedí J; Khoo S; Marzolini C; Calvo-Alcántara MJ; Berenguer J. HIV Medicine. 2020.

Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study.

Schlaeppi C; Vanobberghen F; Sikalengo G; Glass TR; Ndege RC; Foe G; Kuemmerle A; Paris DH; Battegay M; Marzolini C; Weisser M; Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) study group. HIV Medicine. 2020.

Real-life management of drug-drug interactions between antiretrovirals and statins.

Courlet P; Livio F; Alves Saldanha S; Scherrer A; Battegay M; Cavassini M; Stoeckle M; Decosterd LA; Marzolini C; Swiss HIV Cohort Study. Journal of Antimicrobial Chemotherapy. 2020.

Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.

Stader F; Khoo S; Stoeckle M; Back D; Hirsch HH; Battegay M; Marzolini C. . 2020.

The challenge of HIV treatment in an era of polypharmacy.

Back D; Marzolini C. Journal of the International AIDS Society. 2020.

A Comprehensive Framework for Physiologically-Based Pharmacokinetic Modeling in Matlab.

Stader F; Penny MA; Siccardi M; Marzolini C. CPT: pharmacometrics & systems pharmacology. 2019.

Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.

Boyle A; Moss CE; Marzolini C; Khoo S. Clinical Pharmacokinetics. 2019.

Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging.

Sundermann EE; Erlandson KM; Pope CN; Rubtsova A; Montoya J; Moore AA; Marzolini C; O'Brien KK; Pahwa S; Payne BAI; Rubin LH; Walmsley S; Haughey NJ; Montano M; Karris MY; Margolick JB; Moore DJ. AIDS Research and Human Retroviruses. 2019.

Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.

Courlet P; Decosterd LA; Brown JA; Alves Saldanha S; Marzolini C; Cavassini M; Stoeckle M; Csajka C; Labhardt ND; Calmy A; Swiss HIV Cohort Study. Journal of Antimicrobial Chemotherapy. 2019.

Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.

Courlet P; Guidi M; Glatard A; Alves Saldanha S; Cavassini M; Buclin T; Marzolini C; Eap CB; Decosterd LA; Csajka C; Swiss HIV Cohort Study. British Journal of Clinical Pharmacology. 2019.

Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017

Ruffieux Y.; Lemsalu L.; Aebi-Popp K.; Calmy A.; Cavassini M.; Fux C.A.; Gunthard H.F.; Marzolini C.; Scherrer A.; Vernazza P.; Keiser O.; Egger M.; Anagnostopoulos A.; Battegay M.; Bernasconi E.; Boni J.; Braun D.L.; Bucher H.C.; Ciuffi A.; Dollenmaier G.; Elzi L.; Fehr J.; Fellay J.; Furrer H.; Haerry D.; Hasse B.; Hirsch H.H.; Hoffmann M.; Hosli I.; Huber M.; Kahlert C.R.; Kaiser L.; Klimkait T.; Kouyos R.D.; Kovari H.; Ledergerber B.; Martinetti G.; Martinez de Tejada B.; Metzner K.J.; Muller N.; Nicca D.; Paioni P.; Pantaleo G.; Perreau M.; Rauch A.; Rudin C.; Schmid P.; Speck R.; Stockle M.; Tarr P.; Trkola A.; Wandeler G.; Weber R.; Yerly S.T.B.D.. Journal of the International AIDS Society. 2019.

Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.

Hodel EM; Marzolini C; Waitt C; Rakhmanina N. Current Pharmaceutical Design. 2019.

Polypharmacy, drug–drug interactions, and inappropriate drugs: New challenges in the aging population with HIV

Courlet P.; Livio F.; Guidi M.; Cavassini M.; Battegay M.; Stoeckle M.; Buclin T.; Saldanha S.A.; Csajka C.; Marzolini C.; Decosterd L.; Anagnostopoulos A.; Battegay M.; Bernasconi E.; Boni J.; Braun D.L.; Bucher H.C.; Calmy A.; Cavassini M.; Ciuffi A.; Dollenmaier G.; Egger M.; Elzi L.; Fehr J.; Fellay J.; Furrer H.; Fux C.A.; Gunthard H.F.; Haerry D.; Hasse B.; Hirsch H.H.; Hoffmann M.; Hosli I.; Huber M.; Kahlert C.R.; Kaiser L.; Keiser O.; Klimkait T.; Kouyos R.D.; Kovari H.; Ledergerber B.; Martinetti G.; Martinez De Tejada B.; Marzolini C.; Metzner K.J.; Muller N.; Nicca D.; Paioni P.; Pantaleo G.; Perreau M.; Rauch A.; Rudin C.; Scherrer A.U.; Schmid P.; Speck R.; Stockle M.; Tarr P.; Trkola A.; Vernazza P.; Wandeler G.; Weber R.; Yerly S.. Open Forum Infectious Diseases. 2019.

Prescribing issues in elderly individuals living with HIV.

Marzolini C; Livio F. Expert Review of Clinical Pharmacology. 2019.

Prescribing issues in older adults living with HIV: thinking beyond drug-drug interactions with antiretroviral drugs.

Livio F; Marzolini C. . 2019.

Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes.

Stader F; Siccardi M; Battegay M; Kinvig H; Penny MA; Marzolini C. Clinical Pharmacokinetics. 2019.

Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics.

Brockhaus L; Goldblum D; Eggenschwiler L; Zimmerli S; Marzolini C. Clinical Microbiology and Infection. 2019.

UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.

Courlet P; Spaggiari D; Desfontaine V; Cavassini M; Alves Saldanha S; Buclin T; Marzolini C; Csajka C; Decosterd LA. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2019.

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.

Stader F; Kinvig H; Battegay M; Khoo S; Owen A; Siccardi M; Marzolini C. Antimicrobial Agents and Chemotherapy. 2018.

Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.

Baettig V; Courlet P; Delko T; Battegay M; Marzolini C. AIDS. 2018.

Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry

Courlet P.; Spaggiari D.; Cavassini M.; Du Pasquier R.; Alves Saldanha S.; Buclin T.; Marzolini C.; Csajka C.; Decosterd L.. Clinical Mass Spectrometry. 2018.

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.

Ryom L; Boesecke C; Bracchi M; Ambrosioni J; Pozniak A; Arribas J; Behrens G; Mallon P; Puoti M; Rauch A; Miro JM; Kirk O; Marzolini C; Lundgren JD; Battegay M; EACS Governing Board. HIV Medicine. 2018.

HIV and Aging - Perhaps Not as Dramatic as We Feared?

Engel T; Raffenberg M; Marzolini C; Cavassini M; Kovari H; Hasse B; Tarr PE. Gerontology. 2018.

Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.

Bartels H; Decosterd L; Battegay M; Marzolini C. Journal of Antimicrobial Chemotherapy. 2017.

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection.

Seden K; Gibbons S; Marzolini C; Schapiro JM; Burger DM; Back DJ; Khoo SH. PLoS ONE. 2017.

Dolutegravir plasma levels after gastric bypass surgery.

Piso RJ; Battegay M; Marzolini C. AIDS. 2017.

Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.

Marzolini C; Decosterd L; Winterfeld U; Tissot F; Francini K; Buclin T; Livio F. British Journal of Clinical Pharmacology. 2017.

Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems.

Erb S; Letang E; Glass TR; Natamatungiro A; Mnzava D; Mapesi H; Haschke M; Duthaler U; Berger B; Muri L; Bader J; Marzolini C; Elzi L; Klimkait T; Langewitz W; Battegay M; Kilombero Ulanga Antiretroviral Cohort (KIULARCO) study group. HIV Medicine. 2017.

Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.

Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M. Clinical Pharmacokinetics. 2017.

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

Marzolini C; Gibbons S; Khoo S; Back D. Journal of Antimicrobial Chemotherapy. 2016.

Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis.

Scherrer AU; von Wyl V; Yang WL; Kouyos RD; Böni J; Yerly S; Klimkait T; Aubert V; Cavassini M; Battegay M; Furrer H; Calmy A; Vernazza P; Bernasconi E; Günthard HF; Swiss HIV Cohort Study; Aubert V; Battegay M; Bernasconi E; Böni J; Braun DL; Bucher HC; Burton-Jeangros C; Calmy A; Cavassini M; Dollenmaier G; Egger M; Elzi L; Fehr J; Fellay J; Furrer H; Fux CA; Gorgievski M; Günthard H; Haerry D; Hasse B; Hirsch HH; Hoffmann M; Hösli I; Kahlert C; Kaiser L; Keiser O; Klimkait T; Kouyos R; Kovari H; Ledergerber B; Martinetti G; Martinez de Tejada B; Marzolini C; Metzner K; Müller N; Nadal D; Nicca D; Pantaleo G; Rauch A; Regenass S; Rudin C; Schöni-Affolter F; Schmid P; Speck R; Stöckle M; Tarr P; Trkola A; Vernazza P; Weber R; Yerly S. Clinical Infectious Diseases. 2016.

Privacy-preserving genomic testing in the clinic: a model using HIV treatment.

McLaren PJ; Raisaro JL; Aouri M; Rotger M; Ayday E; Bartha I; Delgado MB; Vallet Y; Günthard HF; Cavassini M; Furrer H; Doco-Lecompte T; Marzolini C; Schmid P; Di Benedetto C; Decosterd LA; Fellay J; Hubaux JP; Telenti A. Genetics in Medicine. 2016.

Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.

Moss DM; Marzolini C; Rajoli RK; Siccardi M. Expert opinion on drug metabolism & toxicology. 2015.

Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma.

Kurz M; Stoeckle M; Krasniqi F; Battegay M; Marzolini C. International Journal of STD and AIDS. 2015.

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.

Marzolini C; Sabin C; Raffi F; Siccardi M; Mussini C; Launay O; Burger D; Roca B; Fehr J; Bonora S; Mocroft A; Obel N; Dauchy FA; Zangerle R; Gogos C; Gianotti N; Ammassari A; Torti C; Ghosn J; Chêne G; Grarup J; Battegay M; Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. AIDS. 2015.

Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus.

Lakatos B; Stoeckle M; Elzi L; Battegay M; Marzolini C. Swiss medical weekly. 2014.

Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study.

Hasse B; Iff M; Ledergerber B; Calmy A; Schmid P; Hauser C; Cavassini M; Bernasconi E; Marzolini C; Tarr PE; Swiss HIV Cohort Study; Aubert V; Barth J; Battegay M; Bernasconi E; Böni J; Bucher HC; Burton-Jeangros C; Calmy A; Cavassini M; Egger M; Elzi L; Fehr J; Fellay J; Furrer H; Fux CA; Gorgievski M; Günthard H; Haerry D; Hasse B; Hirsch HH; Hösli I; Kahlert C; Kaiser L; Keiser O; Klimkait T; Kouyos R; Kovari H; Ledergerber B; Martinetti G; Martinez de Tejada B; Metzner K; Müller N; Nadal D; Pantaleo G; Rauch A; Regenass S; Rickenbach M; Rudin C; Schöni-Affolter F; Schmid P; Schultze D; Schüpbach J; Speck R; Staehelin C; Tarr P; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S. Open Forum Infectious Diseases. 2014.

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.

Lubomirov R; Arab-Alameddine M; Rotger M; Fayet-Mello A; Martinez R; Guidi M; di Iulio J; Cavassini M; Günthard HF; Furrer H; Marzolini C; Bernasconi E; Calmy A; Buclin T; Decosterd LA; Csajka C; Telenti A; Swiss HIV Cohort Study. Pharmacogenetics and Genomics. 2013.

Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.

Siccardi M; Marzolini C; Seden K; Almond L; Kirov A; Khoo S; Owen A; Back D. Clinical Pharmacokinetics. 2013.

The brain entry of HIV-1 protease inhibitors is facilitated when used in combination.

Marzolini C; Mueller R; Li-Blatter X; Battegay M; Seelig A. Molecular Pharmaceutics. 2013.

Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

Glass TR; Rotger M; Telenti A; Decosterd L; Csajka C; Bucher HC; Günthard HF; Rickenbach M; Nicca D; Hirschel B; Bernasconi E; Wandeler G; Battegay M; Marzolini C; Swiss HIV Cohort Study.. PLoS ONE. 2012.

Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing.

de Roche M; Siccardi M; Stoeckle M; Livio F; Back D; Battegay M; Marzolini C. Antiviral Therapy. 2012.

Maternal antiretroviral prophylaxis and breastfeeding.

Marzolini C; Gray GE. Antiviral Therapy. 2012.

Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model

Siccardi, M.; Almond, L.; Schipani, A.; Csajka, C.; Marzolini, C.; Wyen, C.; Brockmeyer, N. H.; Boffito, M.; Owen, A.; Back, D.. Clinical Pharmacology and Therapeutics. 2012.

[Drug-drug interactions with HIV treatments].

Mossdorf E; Marzolini C; Fasel D; Mello Fayet A; Blum C; Donath M; Battegay M. Praxis. 2011.

Ageing with HIV: medication use and risk for potential drug-drug interactions.

Marzolini C; Back D; Weber R; Furrer H; Cavassini M; Calmy A; Vernazza P; Bernasconi E; Khoo S; Battegay M; Elzi L; Swiss HIV Cohort Study Members. Journal of Antimicrobial Chemotherapy. 2011.

Mechanisms of Drug Interactions II: Transport Proteins

Marzolini, Catia; Battegay, Manuel; Back, David. . 2011.

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.

Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A; Swiss HIV Cohort Study. Pharmacogenetics and Genomics. 2010.

Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.

Marzolini C; Elzi L; Gibbons S; Weber R; Fux C; Furrer H; Chave JP; Cavassini M; Bernasconi E; Calmy A; Vernazza P; Khoo S; Ledergerber B; Back D; Battegay M; Swiss HIV Cohort Study. Antiviral Therapy. 2010.

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

Elzi L; Marzolini C; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M; Swiss HIV Cohort Study. Archives of Internal Medicine. 2010.

Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.

Mertz D; Battegay M; Marzolini C; Mayr M. American Journal of Kidney Diseases. 2009.

Pharmacogenetics of antiretroviral agents

Marzolini, C; Kim, RB; Telenti, A. . 2008.

Transporter-mediated protection against thiopurine-induced hematopoietic toxicity.

Krishnamurthy P; Schwab M; Takenaka K; Nachagari D; Morgan J; Leslie M; Du W; Boyd K; Cheok M; Nakauchi H; Marzolini C; Kim RB; Poonkuzhali B; Schuetz E; Evans W; Relling M; Schuetz JD. Cancer Research. 2008.

A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression.

Marzolini C; Tirona RG; Gervasini G; Poonkuzhali B; Assem M; Lee W; Leake BF; Schuetz JD; Schuetz EG; Kim RB. Molecular endocrinology (Baltimore, Md.). 2007.

Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.

Colombo S; Béguin A; Marzolini C; Telenti A; Biollaz J; Decosterd LA. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2006.

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

Ribaudo HJ; Haas DW; Tierney C; Kim RB; Wilkinson GR; Gulick RM; Clifford DB; Marzolini C; Fletcher CV; Tashima KT; Kuritzkes DR; Acosta EP; Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases. 2006.

Pharmacogenetics of drug transporters

Marzolini, C; Tirona, R; Kim, RB. . 2005.

Placental transfer of antiretroviral drugs.

Marzolini C; Kim RB. Clinical Pharmacology and Therapeutics. 2005.

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.

Fellay J; Marzolini C; Decosterd L; Golay KP; Baumann P; Buclin T; Telenti A; Eap CB. European Journal of Clinical Pharmacology. 2005.

Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.

Colombo S; Guignard N; Marzolini C; Telenti A; Biollaz J; Decosterd LA. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2004.

MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment

Bleiber, G; May, M; Suarez, C; Martinez, R; Marzolini, C; Egger, M; Telenti, A. Journal of Infectious Diseases. 2004.

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Haas DW; Ribaudo HJ; Kim RB; Tierney C; Wilkinson GR; Gulick RM; Clifford DB; Hulgan T; Marzolini C; Acosta EP. AIDS. 2004.

Pharmacogenomics of the OATP and OAT families.

Marzolini C; Tirona RG; Kim RB. Pharmacogenomics. 2004.

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.

Marzolini C; Paus E; Buclin T; Kim RB. Clinical Pharmacology and Therapeutics. 2004.

Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus

Csajka, C; Marzolini, C; Fattinger, K; Decosterd, LA; Telenti, A; Biollaz, M; Buclin, T. Antimicrobial Agents and Chemotherapy. 2004.

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T. Clinical Pharmacology and Therapeutics. 2003.

Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.

Marzolini C; Béguin A; Telenti A; Schreyer A; Buclin T; Biollaz J; Decosterd LA. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2002.

Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients.

Doser N; Kübli S; Telenti A; Marzolini C; Chave JP; Feihl F; Buclin T; Pannatier A; Darioli R; Nicod P; Waeber B; Mooser V. AIDS. 2002.

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

Fellay J; Marzolini C; Meaden ER; Back DJ; Buclin T; Chave JP; Decosterd LA; Furrer H; Opravil M; Pantaleo G; Retelska D; Ruiz L; Schinkel AH; Vernazza P; Eap CB; Telenti A; Swiss HIV Cohort Study. The Lancet. 2002.

Transplacental passage of protease inhibitors at delivery.

Marzolini C; Rudin C; Decosterd LA; Telenti A; Schreyer A; Biollaz J; Buclin T; Swiss Mother + Child HIV Cohort Study. AIDS. 2002.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T. AIDS. 2001.

Impaired absorption of rifabutin by concomitant administration of didanosine.

Marzolini C; Chave JP; Telenti A; Brenas-Chinchon L; Biollaz J. AIDS. 2001.

Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

Marzolini C; Buclin T; Decosterd LA; Biollaz J; Telenti A. Therapeutic drug monitoring. 2001.

Efavirenz decreases methadone blood concentrations.

Marzolini C; Troillet N; Telenti A; Baumann P; Decosterd LA; Eap CB. AIDS. 2000.

Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.

Marzolini C; Telenti A; Buclin T; Biollaz J; Decosterd LA. Journal of chromatography. B, Biomedical sciences and applications. 2000.

Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.

Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M. Annals of Oncology. 1999.

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.

Marzolini,C; Decosterd,L A; Shen,F; Gander,M; Leyvraz,S; Bauer,J; Buclin,T; Biollaz,J; Lejeune,F. Cancer chemotherapy and pharmacology. 1998.